Detailed Information on Publication Record
2019
Simplified novel prognostic score for real-life older adults with multiple myelomaregistry-based analysis
RADOCHA, J., Roman HÁJEK, Lucie BROŽOVÁ, Luděk POUR, I. ŠPIČKA et. al.Basic information
Original name
Simplified novel prognostic score for real-life older adults with multiple myelomaregistry-based analysis
Authors
RADOCHA, J. (203 Czech Republic, guarantor), Roman HÁJEK (203 Czech Republic), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic, belonging to the institution), I. ŠPIČKA (203 Czech Republic), J. MINAŘÍK (203 Czech Republic), E. GREGORA (203 Czech Republic), A. JUNGOVÁ (203 Czech Republic), T. JELÍNEK (203 Czech Republic), A. HEINDORFER (203 Czech Republic), M. SÝKORA (203 Czech Republic) and V. MAISNAR (203 Czech Republic)
Edition
Annals of hematology, New York, Springer Verlag, 2019, 0939-5555
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30205 Hematology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.904
RIV identification code
RIV/00216224:14110/19:00109477
Organization unit
Faculty of Medicine
UT WoS
000461545800016
Keywords in English
Multiple myeloma; Older adults; Prognostic factors
Tags
International impact, Reviewed
Změněno: 17/4/2019 13:00, Soňa Böhmová
Abstract
V originále
The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65years with symptomatic myeloma were included. The four major parameters with impact on survival were identified: male gender, age>75, creatinine >152mol/L, and ECOG performance status 2-4. The patients were scored as good (0 points), intermediate good (1 point), intermediate poor (2 points), poor (3-4 points). Patients (1410 MM) were included. Median OS (months) was 65.7 (95% CI 49.8-81.7) for good, 51.0 (44.1-57.8) for intermediate good, 32.2 (26.2-38.2) for intermediate poor, and 18.9 (15.1-22.7) for poor. The differences in OS were statistically significant (p<0.0001). Good score was used as reference for hazard ratios, which for each other score were 1.43 (1.09-1.84) for intermediate good, 2.58 (2.00-3.33) for intermediate poor, and 3.88 (2.94-5.10) for poor. Time to progression showed medians (months) 20.5 (17.4-62.4) for good, 19.3 (17.0-21.7) for intermediate good, 19.6 (16.2-23.0) for intermediate poor, and 13.0 (10.8-15.2) for poor. The suggested scoring system provides readily available information about the prognosis of MM patients above 65years.